sorafenib has been researched along with pyrimidine in 3 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (pyrimidine) | Trials (pyrimidine) | Recent Studies (post-2010) (pyrimidine) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 2,159 | 6 | 950 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chung, JY; Hah, JM; Kim, H; Lee, J; Oh, CH; Sim, T; Yoo, KH; Yu, H | 1 |
El-Gamal, MI; Oh, CH | 1 |
Abouzid, KAM; Farag, NA; Lasheen, DS; Mowafy, S; Sobhy, MK | 1 |
3 other study(ies) available for sorafenib and pyrimidine
Article | Year |
---|---|
Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines.
Topics: Antineoplastic Agents; Benzenesulfonates; Binding Sites; Cell Line, Tumor; Crystallography, X-Ray; Drug Discovery; Humans; Imidazoles; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-raf; Pyridines; Pyrimidines; Sorafenib; Structure-Activity Relationship | 2010 |
Diarylureas and diarylamides with pyrrolo[2,3-d]pyrimidine scaffold as broad-spectrum anticancer agents.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Niacinamide; Phenylurea Compounds; Piperazines; Pyrimidines; Pyrroles; Sorafenib | 2014 |
3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: Design, synthesis and biological evaluation.
Topics: Algorithms; Allosteric Site; Binding Sites; Drug Design; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Quantitative Structure-Activity Relationship; Sorafenib; Vascular Endothelial Growth Factor Receptor-2 | 2019 |